{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:50:29Z","timestamp":1765810229451,"version":"3.48.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100634"],"award-info":[{"award-number":["82100634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04412-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:47:24Z","timestamp":1765810044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C"],"prefix":"10.1186","volume":"25","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baima","family":"Yangjin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1","key":"4412_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"4412_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/jvh.13276","volume":"27","author":"G Shiha","year":"2020","unstructured":"Shiha G, Mousa N, Soliman R, et al. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following daas: a prospective study. J Viral Hepat. 2020;27(7):671\u20139.","journal-title":"J Viral Hepat"},{"issue":"13","key":"4412_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975\u201382.","journal-title":"N Engl J Med"},{"issue":"5","key":"4412_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette HJ, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346\u201355.","journal-title":"Ann Intern Med"},{"issue":"6","key":"4412_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"4412_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762\u20138.","journal-title":"J Viral Hepat"},{"issue":"1","key":"4412_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","volume":"62","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Bourli\u00e8re M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79\u201386.","journal-title":"Hepatology"},{"issue":"4","key":"4412_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/hep.28425","volume":"63","author":"S Saab","year":"2016","unstructured":"Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir\/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112\u20139.","journal-title":"Hepatology"},{"key":"4412_CR9","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.2147\/CMAR.S254580","volume":"12","author":"Y Luo","year":"2020","unstructured":"Luo Y, Zhang Y, Wang D, Shen D, Che Y. Eradication of hepatitis C virus (HCV) improves survival of hepatocellular carcinoma patients with active HCV Infection - A Real-World cohort study. Cancer Manag Res. 2020;12:5323\u201330.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"4412_CR10","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.30521","volume":"140","author":"S Manthravadi","year":"2017","unstructured":"Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer. 2017;140(5):1042\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"4412_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and Non-Liver complications. Gastroenterology. 2017;152(1):142\u2013e1562.","journal-title":"Gastroenterology"},{"issue":"2","key":"4412_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12072-018-9851-4","volume":"12","author":"T Ryu","year":"2018","unstructured":"Ryu T, Takami Y, Wada Y, et al. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. Hepatol Int. 2018;12(2):149\u201357.","journal-title":"Hepatol Int"},{"issue":"4","key":"4412_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727\u201333.","journal-title":"J Hepatol"},{"issue":"6","key":"4412_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jvh.12854","volume":"25","author":"M El Kassas","year":"2018","unstructured":"El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis. J Viral Hepat. 2018;25(6):623\u201330.","journal-title":"J Viral Hepat"},{"issue":"6","key":"4412_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312.","journal-title":"J Hepatol"},{"issue":"6","key":"4412_CR16","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-Acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019;156(6):1683\u2013e16921.","journal-title":"Gastroenterology"},{"issue":"2","key":"4412_CR17","first-page":"111","volume":"12","author":"K Imai","year":"2020","unstructured":"Imai K, Takai K, Hanai T, et al. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol. 2020;12(2):111\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"4412_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","volume":"65","author":"H Cardoso","year":"2016","unstructured":"Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65(5):1070\u20131.","journal-title":"J Hepatol"},{"issue":"6","key":"4412_CR19","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/hep.29707","volume":"67","author":"DK Li","year":"2018","unstructured":"Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology. 2018;67(6):2244\u201353.","journal-title":"Hepatology"},{"issue":"5","key":"4412_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(5):933\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"4412_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with Direct-Acting antiviral agents. Gastroenterology. 2017;153(4):996\u2013e10051.","journal-title":"Gastroenterology"},{"issue":"6","key":"4412_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","volume":"17","author":"E Degasperi","year":"2019","unstructured":"Degasperi E, D\u2019Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de Novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with Direct-Acting antivirals for HCV infection. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2019;17(6):1183\u2013e11917.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"1","key":"4412_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Asch SM, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71(1):44\u201355.","journal-title":"Hepatology"},{"issue":"5","key":"4412_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212\u201328.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"4412_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"5 Pt 1","key":"4412_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329\u201337.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4412_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130\u20137.","journal-title":"Hepatology"},{"issue":"8","key":"4412_CR28","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156(8):2149\u201357.","journal-title":"Gastroenterology"},{"issue":"1","key":"4412_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2033-x","volume":"17","author":"L Rinaldi","year":"2019","unstructured":"Rinaldi L, Perrella A, Guarino M, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med. 2019;17(1):292.","journal-title":"J Transl Med"},{"issue":"6","key":"4412_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciw362","volume":"63","author":"M Hedenstierna","year":"2016","unstructured":"Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C. Clin Infect Dis. 2016;63(6):723\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4412_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243473","volume":"15","author":"K Abe","year":"2020","unstructured":"Abe K, Wakabayashi H, Nakayama H, et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One. 2020;15(12):e0243473.","journal-title":"PLoS One"},{"issue":"3","key":"4412_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/infdis\/jiaa359","volume":"226","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nomura H, Nakamuta M, et al. Development of hepatocellular carcinoma in patients aged 75\u201384 years with chronic hepatitis C treated with direct-acting antivirals. J Infect Dis. 2022;226(3):431\u201340.","journal-title":"J Infect Dis"},{"issue":"6","key":"4412_CR33","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.31588","volume":"72","author":"S Alonso L\u00f3pez","year":"2020","unstructured":"Alonso L\u00f3pez S, Manzano ML, Gea F, et al. A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis. Hepatology. 2020;72(6):1924\u201334.","journal-title":"Hepatology"},{"issue":"12","key":"4412_CR34","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1002\/jmv.25984","volume":"92","author":"T Watanabe","year":"2020","unstructured":"Watanabe T, Tokumoto Y, Joko K, et al. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J Med Virol. 2020;92(12):3507\u201315.","journal-title":"J Med Virol"},{"issue":"12","key":"4412_CR35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s11547-023-01726-2","volume":"128","author":"C Zheng","year":"2023","unstructured":"Zheng C, Gu X, Huang X, et al. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study. Radiol Med. 2023;128(12):1460\u201371.","journal-title":"Radiol Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04412-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:47:25Z","timestamp":1765810045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04412-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04412-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Ethics Committee for Human Studies at the First Affiliated Teaching Hospital of Xi\u2019an Jiaotong University. Written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"860"}}